SG11201901203PA - Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients - Google Patents

Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Info

Publication number
SG11201901203PA
SG11201901203PA SG11201901203PA SG11201901203PA SG11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA SG 11201901203P A SG11201901203P A SG 11201901203PA
Authority
SG
Singapore
Prior art keywords
international
treatment
new york
antibodies
hiv
Prior art date
Application number
SG11201901203PA
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
United Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biopharma Inc filed Critical United Biopharma Inc
Publication of SG11201901203PA publication Critical patent/SG11201901203PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201901203PA 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients SG11201901203PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374752P 2016-08-13 2016-08-13
PCT/US2017/046668 WO2018035001A1 (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Publications (1)

Publication Number Publication Date
SG11201901203PA true SG11201901203PA (en) 2019-03-28

Family

ID=61197201

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901203PA SG11201901203PA (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
SG10202100268RA SG10202100268RA (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100268RA SG10202100268RA (en) 2016-08-13 2017-08-13 Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients

Country Status (14)

Country Link
US (1) US11292839B2 (https=)
EP (1) EP3497133A4 (https=)
JP (1) JP2019534891A (https=)
KR (1) KR20190071677A (https=)
CN (1) CN109996815A (https=)
AU (1) AU2017312887A1 (https=)
BR (1) BR112019002734A2 (https=)
CA (1) CA3033728A1 (https=)
MX (1) MX2019001814A (https=)
RU (1) RU2019106804A (https=)
SG (2) SG11201901203PA (https=)
TW (1) TW201808998A (https=)
WO (1) WO2018035001A1 (https=)
ZA (1) ZA201901374B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190071677A (ko) * 2016-08-13 2019-06-24 유나이티드 바이오파마, 인크. Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
AU2020275049A1 (en) * 2019-05-16 2022-01-06 Nanjing Legend Biotech Co., Ltd. Engineered immune cells comprsing a recognition molecule
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
EP4716750A1 (en) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU662891B2 (en) 1990-11-27 1995-09-21 Biogen Idec Ma Inc. Anti CD-4 antibodies blocking HIV-induced syncytia
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
DE69535002T2 (de) 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1083226A4 (en) 1998-05-25 2001-12-19 Asahi Chemical Ind DEVICE FOR SEPARATING CELLS AND SEPARATION METHOD.
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
CO5160259A1 (es) 1999-03-02 2002-05-30 Schering Corp Interferon alfa pegilado en la terapia contra el hiv
CA2469901C (en) 2001-12-11 2017-07-04 Biotectid Gmbh Use of a labelled ligand having specificity for the human cd4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of cell populations
JP2003327536A (ja) 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20030211470A1 (en) 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
US20090232826A1 (en) 2005-05-02 2009-09-17 Mymetics Corporation Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
RU2393873C2 (ru) 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
WO2007025276A2 (en) 2005-08-25 2007-03-01 Government Of The United States Of America, As Represented By The Secretary Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
CA2884430A1 (en) 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
AU2014269042A1 (en) * 2013-05-24 2015-12-03 Cooper Human Systems Llc Methods and compositions for treatment of HIV infection
MX2017003546A (es) 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.
KR20190071677A (ko) * 2016-08-13 2019-06-24 유나이티드 바이오파마, 인크. Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화

Also Published As

Publication number Publication date
BR112019002734A2 (pt) 2019-05-14
ZA201901374B (en) 2022-04-28
TW201808998A (zh) 2018-03-16
WO2018035001A1 (en) 2018-02-22
JP2019534891A (ja) 2019-12-05
RU2019106804A (ru) 2020-09-21
EP3497133A1 (en) 2019-06-19
RU2019106804A3 (https=) 2021-03-29
EP3497133A4 (en) 2020-03-25
CN109996815A (zh) 2019-07-09
CA3033728A1 (en) 2018-02-22
MX2019001814A (es) 2019-07-08
SG10202100268RA (en) 2021-02-25
AU2017312887A1 (en) 2019-03-07
US20190194326A1 (en) 2019-06-27
US11292839B2 (en) 2022-04-05
KR20190071677A (ko) 2019-06-24

Similar Documents

Publication Publication Date Title
SG11201901203PA (en) Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201909547TA (en) Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201909949XA (en) Targeted immunotolerance
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201901950TA (en) Methods of treating immune disorders using pd-1 binding proteins
SG11201803906PA (en) Control of cellular redox levels
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201805001UA (en) Method of treating influenza a
SG11201808125RA (en) Methods for solid tumor treatment
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201901303WA (en) A handheld hair care appliance
SG11201810454YA (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment